US EditionBaker McKenzie Advises Takeda In Global Strategic Partnership With Innovent Biologics.
Innovent and Takeda will co-develop and commercialize next-gen immuno-oncology and antibody-drug conjugate therapies with a deal valued up to $11.4 billion, accelerating global cancer treatment.
- Innovent Biologics and Takeda announced a global collaboration on Wednesday, October 22, 2025, to advance next-generation IO and ADC cancer therapies in a company webcast and conference call.
- The companies said the deal will leverage Innovent's IO and ADC R&D and Takeda's global oncology development to accelerate two late-stage investigational medicines worldwide.
- The agreement covers IBI363, IBI343 and IBI3001, with IBI363 co-developed globally sharing development costs 40/60 and IBI3001 under an exclusive option outside Greater China.
- Financially, the deal includes an upfront US$1.2 billion payment to Innovent, including a US$100 million equity investment at HK$112.56 per share, with a total deal value up to $11.4Billion.
- IBI363 is entering registrational development with a global Phase 3 in second-line sqNSCLC expected in the coming months and ASCO 2025 data from over 1,200 treated patients support expansion.
33 Articles
33 Articles
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market (2025-10-21)
The collaboration combines Innovent's proven immuno-oncology and antibody-drug conjugate R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program. Innovent and Takeda will co-develop the IO...
Helena Independent Record
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.Innovent and Takeda…
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market - Innovent Biologics (OTC:IVBIY), Takeda Pharmaceutical Co (NYSE:TAK)
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program. Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., wher…
Baker McKenzie Advises Takeda In Global Strategic Partnership With Innovent Biologics.
Baker McKenzie represented Takeda in its global strategic partnership with Innovent Biologics, bolstering Takeda’s oncology pipeline with next-generation investigational medicines for the treatment of solid tumors. Under terms of the agreement, Takeda will gain rights to two late-stage oncology assets —IBI363 and IBI343—outside Greater China, and an exclusive option to license an early-stage program. IBI363, a bispecific antibody fusion protein,…
Coverage Details
Bias Distribution
- 93% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
